Skandinaviska Enskilda Banken AB publ Takes Position in Olink Holding AB (publ) (NASDAQ:OLK)

Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Olink Holding AB (publ) (NASDAQ:OLK) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 170,265 shares of the company’s stock, valued at approximately $4,338,000. Skandinaviska Enskilda Banken AB publ owned 0.14% of Olink Holding AB (publ) as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. UBS Group AG increased its position in Olink Holding AB (publ) by 5,531.1% during the 4th quarter. UBS Group AG now owns 253,400 shares of the company’s stock valued at $6,373,000 after purchasing an additional 248,900 shares during the period. Assetmark Inc. lifted its position in Olink Holding AB (publ) by 30.5% during the 4th quarter. Assetmark Inc. now owns 2,874 shares of the company’s stock worth $72,000 after acquiring an additional 672 shares during the period. Carmignac Gestion acquired a new position in Olink Holding AB (publ) in the 4th quarter worth approximately $3,104,000. Gardner Lewis Asset Management L P purchased a new position in shares of Olink Holding AB (publ) during the fourth quarter worth $10,403,000. Finally, Gabelli Funds LLC acquired a new position in shares of Olink Holding AB (publ) in the 4th quarter valued at about $9,513,000. 30.19% of the stock is currently owned by institutional investors.

Olink Holding AB (publ) Price Performance

Shares of NASDAQ OLK opened at $26.08 on Monday. Olink Holding AB has a 12 month low of $14.10 and a 12 month high of $26.09. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -96.59 and a beta of 0.52. The firm’s 50 day simple moving average is $26.08 and its 200-day simple moving average is $24.76.

Olink Holding AB (publ) Profile

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.